Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases.
Identifieur interne : 000934 ( Main/Exploration ); précédent : 000933; suivant : 000935Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases.
Auteurs : RBID : pubmed:22591909English descriptors
- KwdEn :
- Adult, Bone Neoplasms (diagnosis), Bronchial Neoplasms (pathology), Carcinoma, Neuroendocrine (pathology), Diffusion Magnetic Resonance Imaging (methods), Female, Humans, Indium Radioisotopes (diagnostic use), Liver Neoplasms (diagnosis), Liver Neoplasms (secondary), Lung Neoplasms (diagnosis), Lung Neoplasms (pathology), Lung Neoplasms (secondary), Lymphatic Metastasis, Male, Somatostatin (analogs & derivatives), Somatostatin (diagnostic use), Tomography, X-Ray Computed (methods), Whole Body Imaging (methods), Young Adult.
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , diagnostic use : Indium Radioisotopes, Somatostatin.
- diagnosis : Bone Neoplasms, Liver Neoplasms, Lung Neoplasms.
- methods : Diffusion Magnetic Resonance Imaging, Tomography, X-Ray Computed, Whole Body Imaging.
- pathology : Bronchial Neoplasms, Carcinoma, Neuroendocrine, Lung Neoplasms.
- secondary : Liver Neoplasms, Lung Neoplasms.
- Adult, Female, Humans, Lymphatic Metastasis, Male, Young Adult.
Abstract
Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs.
DOI: 10.1186/1477-7819-10-82
PubMed: 22591909
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases.</title><author><name sortKey="Cossetti, Rachel Jorge D" uniqKey="Cossetti R">Rachel Jorge D Cossetti</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Oncologia, Hospital Sírio Libanês, Rua Dona Adma Jafet 91, São Paulo 01308-050, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Centro de Oncologia, Hospital Sírio Libanês, Rua Dona Adma Jafet 91, São Paulo 01308-050</wicri:regionArea></affiliation></author><author><name sortKey="Bezerra, Regis Otaviano Franca" uniqKey="Bezerra R">Regis Otaviano França Bezerra</name></author><author><name sortKey="Gumz, Brenda" uniqKey="Gumz B">Brenda Gumz</name></author><author><name sortKey="Telles, Adriana" uniqKey="Telles A">Adriana Telles</name></author><author><name sortKey="Costa, Frederico P" uniqKey="Costa F">Frederico P Costa</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1186/1477-7819-10-82</idno><idno type="RBID">pubmed:22591909</idno><idno type="pmid">22591909</idno><idno type="wicri:Area/Main/Corpus">000D04</idno><idno type="wicri:Area/Main/Curation">000D04</idno><idno type="wicri:Area/Main/Exploration">000934</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Bone Neoplasms (diagnosis)</term><term>Bronchial Neoplasms (pathology)</term><term>Carcinoma, Neuroendocrine (pathology)</term><term>Diffusion Magnetic Resonance Imaging (methods)</term><term>Female</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Liver Neoplasms (diagnosis)</term><term>Liver Neoplasms (secondary)</term><term>Lung Neoplasms (diagnosis)</term><term>Lung Neoplasms (pathology)</term><term>Lung Neoplasms (secondary)</term><term>Lymphatic Metastasis</term><term>Male</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (diagnostic use)</term><term>Tomography, X-Ray Computed (methods)</term><term>Whole Body Imaging (methods)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Somatostatin</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Bone Neoplasms</term><term>Liver Neoplasms</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Diffusion Magnetic Resonance Imaging</term><term>Tomography, X-Ray Computed</term><term>Whole Body Imaging</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Bronchial Neoplasms</term><term>Carcinoma, Neuroendocrine</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Liver Neoplasms</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Male</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22591909</PMID><DateCreated><Year>2012</Year><Month>10</Month><Day>16</Day></DateCreated><DateCompleted><Year>2013</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7819</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>World journal of surgical oncology</Title><ISOAbbreviation>World J Surg Oncol</ISOAbbreviation></Journal><ArticleTitle>Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases.</ArticleTitle><Pagination><MedlinePgn>82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1477-7819-10-82</ELocationID><Abstract><AbstractText>Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cossetti</LastName><ForeName>Rachel Jorge D</ForeName><Initials>RJ</Initials><Affiliation>Centro de Oncologia, Hospital Sírio Libanês, Rua Dona Adma Jafet 91, São Paulo 01308-050, Brazil.</Affiliation></Author><Author ValidYN="Y"><LastName>Bezerra</LastName><ForeName>Regis Otaviano França</ForeName><Initials>RO</Initials></Author><Author ValidYN="Y"><LastName>Gumz</LastName><ForeName>Brenda</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Telles</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Frederico P</ForeName><Initials>FP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Case Reports</PublicationType><PublicationType>Comparative Study</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Surg Oncol</MedlineTA><NlmUniqueID>101170544</NlmUniqueID><ISSNLinking>1477-7819</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>138661-02-6</RegistryNumber><NameOfSubstance>pentetreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>AJR Am J Roentgenol. 2008 Jan;190(1):67-73</RefSource><PMID Version="1">18094295</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2005 Nov;16(11):1806-10</RefSource><PMID Version="1">16085691</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):577-83</RefSource><PMID Version="1">16183528</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Abdom Imaging. 1999 Sep-Oct;24(5):456-61</RefSource><PMID Version="1">10475927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surgery. 1990 Dec;108(6):1091-6</RefSource><PMID Version="1">1701060</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJR Am J Roentgenol. 2003 Jan;180(1):121-8</RefSource><PMID Version="1">12490490</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Radiol. 2008 Mar;18(3):486-92</RefSource><PMID Version="1">17994317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Surg. 2000 Apr;190(4):432-45</RefSource><PMID Version="1">10757381</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Radiol. 2001 Nov;74(887):1065-70</RefSource><PMID Version="1">11709476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Radiol. 2010 Sep;75(3):376-83</RefSource><PMID Version="1">19497694</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2010 May;51(5):669-73</RefSource><PMID Version="1">20395323</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2010 Mar;51(3):353-9</RefSource><PMID Version="1">20150249</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JOP. 2009;10(5):528-31</RefSource><PMID Version="1">19734630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Nucl Med. 2008 Jun;22(5):395-401</RefSource><PMID Version="1">18600417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jun 20;26(18):3063-72</RefSource><PMID Version="1">18565894</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Bronchial Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Neuroendocrine</DescriptorName><QualifierName MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="Y">pathology</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Whole Body Imaging</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3472201</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">1477-7819-10-82</ArticleId><ArticleId IdType="doi">10.1186/1477-7819-10-82</ArticleId><ArticleId IdType="pubmed">22591909</ArticleId><ArticleId IdType="pmc">PMC3472201</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000934 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000934 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22591909
|texte= Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22591909" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |